CORONA Remedies IPO draws attention with strong GMP and branded chronic pharma focus
Strong grey market sentiment lifted interest in the CORONA Remedies IPO, even as investors weighed its pure offer-for-sale structure, premium valuation, and reliance on chronic therapy segments.